Flu

The Pharmacy Times® Flu resource center provides information about early symptoms of the flu and the array of therapies in development intended to treat it as it progresses. Additionally, learn more about the data coming directly from the most widely attended pharmacy conferences and meetings, updated clinical trial listings, and other resources.

Beyond the Bench: Advancing Vaccine Education
What can we help you find?
[[thumbnail_alt_text]]
Educating Patients on the Correct Use of Treatments Can Lower the Risk of Influenza Complications and Severity
[[thumbnail_alt_text]]
Originally approved in 2018, baloxavir marboxil is indicated for patients aged 12 years and older.
[[thumbnail_alt_text]]
In the midst of a pandemic, visibility and interoperability have never been more critical when it comes to medication inventory.
[[thumbnail_alt_text]]
The NCPA and NACDS both applauded the HHS announcement regarding the partnerships with national and regional chain pharmacies and independent pharmacies to maximize access to COVID-19 vaccines.
[[thumbnail_alt_text]]
The findings show that vaping changes the expression of genes and production of proteins in respiratory cells, as well as altering virus-specific antibody production, according to the study.
[[thumbnail_alt_text]]
A new study found that more than half of COVID-19 patients continue to feel fatigued 10 weeks after illness onset. 

 
[[thumbnail_alt_text]]
Advise patients it is not too late to get vaccinated and is imperative amid the pandemic.
[[thumbnail_alt_text]]
A majority of young adults with cardiovascular disease are not receiving the annual influenza vaccine despite their heightened risk of secondary infections.
[[thumbnail_alt_text]]
The study suggests that if 10% of people given the test had previously been infected, approximately 1 in 5 positive test results would be incorrect, showing false positive results.
[[thumbnail_alt_text]]
The transmission of COVID-19 depends almost entirely on human behavior, meaning temperature and humidity do not play a significant role, study suggests.
 
[[thumbnail_alt_text]]
Investigational COVID-19 antibody was authorized in a 700 mg dose for adults and pediatric patients 12 years and older and should be administered as soon as possible after diagnosis and within 10 days of symptom onset.
 
[[thumbnail_alt_text]]
A new study suggests that COVID-19 antibodies remain in the body for up to 5 months.